CGT Catapult announced its partnership with TrakCel this week, explaining the UK firm’s supply chain management platform will be used to track cell and gene therapies made at the facility and stored at an adjacent warehouse being built by Fisher Bioservices.
A TrakCel spokesman told us “As part of their offering to clients using the Stevenage site, CGT Catapult are providing IT infrastructure so clients do not have to invest in this themselves if they decide to perform manufacturing operations in Stevenage.”
He added that the aim is to provide clients with an overview of the progress of therapies through the supply chain, explaining the system also captures data from cell collection, couriers and treatment centres.
“Stevenage covers only a part of the cell and gene therapy supply chain. If the client feels that they need only data captured by the CGTC and Fisher systems ‘off the shelf’ any costs will be incorporated into the fees charged by those companies” the spokesman said.
"TrakCel can capture data on factors that can impact on product quality. Depending on the client’s choice of courier, shipping system and monitoring device – and provided these are integrated with TrakCel, we can capture data such as temperature, humidity, orientation, shock, location.”
In addition to the ability to trace cell and gene therapies, the TrakCel system also provides automated alerts to keep doctors, patients and all other stakeholders informed about their progress through supply chains.
According to CGT Catapult the Stevenage facility is on track to be operation later this year.